Novartis mulls outcome-based price for CAR T therapy

Novartis AG (NYSE:NVS; SIX:NOVN) is considering outcome-based payment models for tisagenlecleucel-T (CTL019), its chimeric antigen receptor T cell therapy under FDA review to treat pediatric and young adult relapsed or refractory B cell acute lymphoblastic leukemia (ALL). The treatment, whose PDUFA date is Oct. 3, could become the first FDA-approved CAR T therapy.

In response to an analyst's question during Novartis' 2Q17 earnings call Tuesday, Novartis Oncology CEO Bruno Strigini said the company is "looking at a number of options, including health economic models and also outcome models that consider the significant value CTL019 brings to patients, its scientific innovation and the high cost of manufacturing." He said tisagenlecleucel-T's price will be revealed at launch...